Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Esperion Theraptc (NQ: ESPR )

2.159 +0.099 (+4.79%)
Streaming Delayed Price Updated: 12:19 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Esperion Theraptc

< Previous 1 2 3 Next >
Esperion to Report Fourth Quarter and Full Year 2022 Financial Results February 21, 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
NASCAR Champion Brad Keselowski to Run No. 6 NEXLIZET (bempedoic acid and ezetimibe) Ford in Famed Daytona 500 
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Outlines Upcoming Milestones and Announces Preliminary Fourth Quarter 2022 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology (ACC.23/WCC)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in January Investor Meetings
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Appoints Ben Halladay Chief Financial Officer
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Virtual Research & Development Day to Highlight Pipeline Programs and Scientific Focus
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Jefferies London Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Reports Third Quarter 2022 Financial Results and Provides Company Update
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Hosting Virtual Research & Development Day
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Report Third Quarter 2022 Financial Results November 1, 2022
From Esperion Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.